pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX
TG THERAPEUTICS
TG THERAPEUTICS, INC.
TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
- Founded
- 2011
- Employees
- 521
- Programs
- 39
- Drugs
- 23
- Patents
- 7
Ublituximab + TGR-1202
Phase 1 · small molecule · Chronic Lymphocytic Leukemia
Ublituximab + TGR-1202 for Chronic Lymphocytic Leukemia is a Phase 1 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code UTX-TGR-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TG THERAPEUTICS, INC.
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Chronic Lymphocytic Leukemia
- Status
- completed
- Trials
- 1